Published in Oncology on March 21, 2007
Current status of bevacizumab in advanced ovarian cancer. Onco Targets Ther (2013) 0.85
Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. Cancer (2010) 0.82
Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Jpn J Clin Oncol (2008) 0.77
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
Ovarian cancer. Lancet (2009) 3.95
Use, costs and comparative effectiveness of robotic assisted, laparoscopic and open urological surgery. J Urol (2012) 2.94
Hospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy. J Urol (2012) 2.79
Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy. J Urol (2010) 2.77
Economic costs of overactive bladder in the United States. Urology (2009) 2.68
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol (2011) 2.62
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
Influence of surgeon and hospital volume on radical prostatectomy costs. J Urol (2012) 2.37
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.24
Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology (2011) 2.24
Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach. J Urol (2012) 2.22
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation. Gynecol Oncol (2009) 2.15
Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int (2013) 2.12
Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol (2011) 2.09
Comparison of outpatient narcotic prescribing patterns after minimally invasive versus retropubic and perineal radical prostatectomy. J Urol (2011) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol (2004) 1.96
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol (2012) 1.78
Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample. Eur Urol (2011) 1.76
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology (2013) 1.63
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.62
Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol (2010) 1.58
Trends in the care of radical prostatectomy in the United States from 2003 to 2006. BJU Int (2010) 1.57
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
Quality of life, pain and return to normal activities following laparoscopic donor nephrectomy versus open mini-incision donor nephrectomy. J Urol (2003) 1.47
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. Gynecol Oncol (2007) 1.47
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol (2005) 1.45
Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function. Eur Urol (2012) 1.45
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer (2014) 1.41
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. Gynecol Oncol (2005) 1.41
2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA (2012) 1.41
Laparoscopic supracervical hysterectomy for benign gynecologic conditions. JSLS (2009) 1.40
Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med (2014) 1.39
A rare case of precoccygeal endometriosis. Obstet Gynecol (2006) 1.39
Randomized controlled trial of barbed polyglyconate versus polyglactin suture for robot-assisted laparoscopic prostatectomy anastomosis: technique and outcomes. Eur Urol (2010) 1.38
Refocusing the debate: evidence-based clinical cancer research versus marketplace reality. J Oncol Pract (2008) 1.38
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol (2010) 1.33
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol (2010) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Paclitaxel in cancer therapy. Expert Opin Pharmacother (2002) 1.26
The management of recurrent ovarian cancer. Semin Oncol (2007) 1.22
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer (2009) 1.18
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol (2004) 1.15
Overuse of imaging for staging low risk prostate cancer. J Urol (2011) 1.14
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood (2007) 1.14
Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord (2003) 1.13
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab (2009) 1.13
Pilot study assessing robotic laparoscopic hysterectomy and patient outcomes. J Minim Invasive Gynecol (2006) 1.12
Acanthosis nigricans with endometrial carcinoma: case report and review of the literature. Gynecol Oncol (2002) 1.10
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer (2009) 1.08
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2002) 1.08
Role of nutritional status in predicting quality of life outcomes in cancer--a systematic review of the epidemiological literature. Nutr J (2012) 1.07
Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol (2005) 1.06
The increasingly complex world of cancer patient advocacy organizations. Curr Oncol Rep (2008) 1.04
Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol (2006) 1.04
Contemporary diagnosis and management of a uterine arteriovenous malformation. Obstet Gynecol (2008) 1.03
Perivascular epithelioid cell neoplasms: a systematic review of prognostic factors. J Minim Invasive Gynecol (2009) 1.03
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int (2011) 1.03
Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol (2009) 1.03
Overcoming the learning curve for robotic-assisted laparoscopic radical prostatectomy. Urol Clin North Am (2010) 1.03
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol (2006) 1.03
The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management. Gynecol Oncol (2007) 1.02
Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer. J Sex Med (2010) 1.02
Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol (2005) 1.01
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys (2011) 1.00
Serous psammocarcinoma of the ovary: an unusual finding. Gynecol Oncol (2005) 1.00
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol (2014) 1.00
Viewing ovarian cancer as a "chronic disease": what exactly does this mean? Gynecol Oncol (2005) 1.00
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol (2002) 0.99
Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol (2005) 0.99